JP Morgan Chase
ADXN

JP Morgan Chase’s Addex Therapeutics ADXN Stock Holding History

JP Morgan Chase’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79
Closed -$699 – 7361
2025
Q2 		$699 Buy
+79
New +$639 ﹤0.01% 6660

Other funds holding ADXN

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's ADXN Position: Q3 2025 in Review

JP Morgan Chase sold out of Addex Therapeutics (ADXN) in Q3 2025, closing a stake of 79 shares — an estimated $699 sold.

JP Morgan Chase first reported a position in ADXN in Q2 2025 and held it in 1 quarter. The position peaked at $699 in Q2 2025. 4 funds tracked by Wall St. Rank hold ADXN as of Q3 2025.

  • JP Morgan Chase reported no remaining Addex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 79 Addex Therapeutics shares in Q3 2025, an estimated $699.
  • JP Morgan Chase first reported a position in Addex Therapeutics in Q2 2025 and held it in 1 quarter.
  • JP Morgan Chase's Addex Therapeutics position peaked at $699 in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Addex Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.